EQL Pharma Wins Approval to Sell Melatonin Tablets in Kazakhstan

MT Newswires · 2d ago
05:17 AM EDT, 07/15/2026 (MT Newswires) -- EQL Pharma (EQL.ST) said Wednesday that its regional partner Abdi Ibrahim secured marketing approval in Kazakhstan for the 3-milligram strength of its Mellozzan tablets. The Swedish pharmaceutical company expects the 5-mg strength to be approved in December 2026, with the commercial launch of both doses expected in fiscal 2028. Mellozzan contains the sleep hormone melatonin and is indicated for children with attention-deficit/hyperactivity disorder who experience sleep difficulties.